ResearcherSichuan UniversityActive in the last 2 years
Xiaorui Zhu
Matched on ORCID iD 0000-0003-3611-0263; OpenAlex author ID A5158863702. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 18
2025: 1 paper · 2026: 2 papers
Papers 3
- Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcinoma: a multicenter, single-arm, phase II … Co-author DOI 10.1158/1078-0432.ccr-26-1824↗
- Safety and efficacy of the MNK/VEGFR inhibitor JDB153 combined with the anti-PD-1 antibody serplulimab in patients with advanced pancreatic cancer refractory t… Co-author DOI 10.3389/fphar.2026.1805590↗
- RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line treatment for metastatic pancreatic adenocar… Co-author DOI 10.21203/rs.3.rs-7291840/v1↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Dan Cao · 3 shared papers, 2025–2026 · strength 0.79
- Paper Safety and efficacy of the MNK/VEGFR inhibitor JDB153 combined with the anti-PD-1 antibody serplulimab in patients with… DOI 10.3389/fphar.2026.1805590↗
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
- Huanji Xu · 2 shared papers, 2025–2026 · strength 0.59
- Paper Safety and efficacy of the MNK/VEGFR inhibitor JDB153 combined with the anti-PD-1 antibody serplulimab in patients with… DOI 10.3389/fphar.2026.1805590↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
- Zixing Huang · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
- Chen Chang · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
- Junjie Xiong · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
- Yi Cheng · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
- Ke Cheng · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
- Qingqing Leng · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
- Wanting Hou · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
- Chenyan Zhang · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
- Yi Zhang · 1 shared paper, 2026 · strength 0.19
- Bole Tian · 1 shared paper, 2026 · strength 0.19
- Chengjian Zhao · 1 shared paper, 2025 · strength 0.16
- Xiaoying Li · 1 shared paper, 2025 · strength 0.16
- Yi Zhang · 1 shared paper, 2025 · strength 0.16
- Bole Tian · 1 shared paper, 2025 · strength 0.16
- Rui Wang · 1 shared paper, 2025 · strength 0.16
- Bo Chen · 1 shared paper, 2025 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.